Share this article
Microcap Biotech Firm Raises $212M for Prediction Market Token Treasury Strategy
Enlivex Therapeutics is raising $212 million to invest in RAIN, the token of a blockchain-based prediction market, which will become its main treasury reserve asset.
Nov 24, 2025, 1:00 p.m.
Make us preferred on Google
What to know:
- Enlivex Therapeutics is raising $212 million to invest in RAIN, the token of a blockchain-based prediction market, which will become its main treasury reserve asset.
- The token powers a decentralized protocol for creating and trading prediction markets on real-world events.
- The investment won't affect Enlivex's clinical trials for its lead drug candidate, Allocetra, and will also bring Italy's former prime minister, Matteo Renzi, to its board of directors.
Enlivex Therapeutics (ENLV), an Israel-based clinical-stage biotech firm, said it’s raising $212 million in a private placement to become the first publicly traded U.S. company to adopt a blockchain-based prediction markets token as its main treasury reserve asset.
The token, RAIN, powers a decentralized protocol built on the Arbitrum blockchain that allows users to create and trade predictions markets on real-world events using smart contracts.
STORY CONTINUES BELOW
Don't miss another story.Subscribe to the Crypto Daybook Americas Newsletter today. See all newsletters
As with other prediction markets, like Polymarket, traders on Rain can bet on topics ranging from elections to sports, with outcomes settled via oracles or AI-based tools. The platform also includes a deflationary “buyback and burn” mechanism aimed at curbing supply of the RAIN token.
Enlivex, which has a $22 million market cap on Nasdaq, plans to buy RAIN tokens with the majority of the funds raised and will use the asset as its core treasury holding. The firm said it sees the growing prediction markets space as a strategic growth area, citing recent investments in competitors like Polymarket and Kalshi by major institutions including the New York Stock Exchange’s parent company and Andreessen Horowitz.
At the same time, Enlivex will continue clinical trials for its lead drug candidate, Allocetra, a macrophage therapy for osteoarthritis, according to a press release shared with CoinDesk. The disease affects more than 30 million Americans and lacks treatments that halt joint damage, a gap Allocetra aims to address.
Matteo Renzi, Italy’s former prime minister, is expected to join Enlivex’s board following the deal’s close, set for Nov. 25. Last year, the company’s board of directors added bitcoin to its cash-management strategy, approving the purchase of up to $1 million in the cryptocurrency. It’s unclear how much, if any, BTC the company currently holds.
The transaction, priced at $1 per share, represents an 11.5% premium over Enlivex’s last trading price.
AI Disclaimer: Parts of this article were generated with the assistance from AI tools and reviewed by our editorial team to ensure accuracy and adherence to our standards. For more information, see CoinDesk's full AI Policy.
More For You
More For You
Prediction markets vs. insider trading: Founders admit blockchain transparency is the only defense
Prediction markets are increasingly being framed not as gambling platforms but as vehicles for monetizing information, though founders acknowledged the line can blur.
What to know:
- Founders argue prediction markets monetize information, though user intent varies.
- Onchain transparency helps, but information asymmetry remains a core challenge.
- How platforms address manipulation and disclosure will shape institutional acceptance.
Top Stories
